SLC16A1 and breast carcinoma: To test the consequences of MCT1 inhibition by AZD3965 on cancer and nonmalignant cells representative of the breast tissue, we chose as models T47D human ductal carcinoma breast cancer cells, MCF7 human breast adenocarcimoma cancer cells, nonmalignant MCF10A human epithelial breast cells and human BJ fibroblasts.